Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027819 (neuroblastoma)
 27,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The Executive Committee of the B.A.P.S. instituted a collaborative study of patients with thoracic neuroblastoma treated by members in the British Isles. The study covers patients diagnosed in the decade 1970-1979. There is clear evidence of thoracic disease in all patients reported but there is a problem in defining whether the thoracic disease is primary or part of disseminated disease. In 9 of the deaths the thoracic component at presentations seems likely to be part of a generalised disease without definition of a primary site. Overall mortality in this series is 35% indicating the better prognosis of the patients presenting with thoracic neuroblastoma compared to other primary sites. If the 9 patients considered to have generalised disease are excluded then the mortality in this collected series is 22% (10 of 45). The investigations and management are outlined and the complications of therapy are considered.
 ...
PMID:Thoracic neuroblastoma/ganglioneuroma. 683 25

From January, 1969 through July, 1979, 37 children with neuroblastoma were cared for at the Oklahoma Children's Memorial Hospital. Nineteen patients with extensive disease were studied to examine the interrelationships of chemotherapy, radiation therapy and secondary surgery. Eleven children had secondary surgery in the abdomen or cervical region with one postoperative death. All patients had chemotherapy and ten had radiation therapy between the primary and secondary operation or death. Five children survived. Four of five survivors were less than one year of age at diagnosis and initial treatment. Fourteen of 15 patients, one year of age or older, died. Each case had pathologic examination of tumor before and after therapy. All survivors showed sequential maturation of tumor tissue but only one nonsurvivor had this finding. Unusual metastatic spread was found in patients having combined therapy. Multimodal therapy for advanced neuroblastoma accentuates the need for sensible timing and utilization of secondary operative procedures. The secondary procedures ideally eradicate the primary focus of tumor, and may also serve to excise selective areas of metastatic disease or to biopsy residual disease in aiding continuing therapy. Secondary surgery ought to follow the onset of radiation therapy by four to six weeks, or of chemotherapy by 12 to 24 weeks. This delay allows maximum control of primary and generalized disease, as well as maturation, differentiation, encapsulation and shrinkage of extensive initially unresectable primary tumors.
 ...
PMID:The impact of chemotherapy and radiation therapy on secondary operations for neuroblastoma. 736 19